Vericel CorpNASDAQ:VCEL
- LAST PRICE42.7150
- TODAY'S CHANGE (%)-0.4750 (-1.0998%)
- Bid / Lots42.6400/ 2
- Ask / Lots42.8200/ 2
- Open / Previous Close42.8900 / 43.1900
- Day Range
- 52 Week Range
- Volume92,211
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VCEL |
|---|---|---|
| 09:32 ET | 1652 | 43.18 |
| 09:36 ET | 200 | 43.14 |
| 09:41 ET | 100 | 43.055 |
| 09:45 ET | 200 | 43.24 |
| 09:48 ET | 200 | 43.315 |
| 09:50 ET | 1319 | 43.45 |
| 09:52 ET | 500 | 43.505 |
| 09:54 ET | 611 | 43.535 |
| 09:56 ET | 200 | 43.65 |
| 09:57 ET | 1040 | 43.525 |
| 09:59 ET | 500 | 43.58 |
| 10:01 ET | 272 | 43.691 |
| 10:03 ET | 100 | 43.53 |
| 10:08 ET | 100 | 43.615 |
| 10:10 ET | 657 | 43.5889 |
| 10:12 ET | 100 | 43.625 |
| 10:14 ET | 225 | 43.63 |
| 10:15 ET | 100 | 43.61 |
| 10:17 ET | 100 | 43.61 |
| 10:19 ET | 952 | 43.59 |
| 10:21 ET | 460 | 43.63 |
| 10:24 ET | 300 | 43.615 |
| 10:26 ET | 101 | 43.605 |
| 10:28 ET | 485 | 43.59 |
| 10:32 ET | 650 | 43.59 |
| 10:33 ET | 355 | 43.495 |
| 10:37 ET | 300 | 43.54 |
| 10:39 ET | 803 | 43.525 |
| 10:42 ET | 395 | 43.57 |
| 10:44 ET | 100 | 43.49 |
| 10:46 ET | 200 | 43.485 |
| 10:48 ET | 1094 | 43.5 |
| 10:50 ET | 100 | 43.495 |
| 10:51 ET | 100 | 43.495 |
| 10:53 ET | 400 | 43.415 |
| 10:55 ET | 412 | 43.42 |
| 11:00 ET | 2170 | 43.32 |
| 11:02 ET | 1233 | 43.52 |
| 11:06 ET | 3008 | 43.605 |
| 11:09 ET | 100 | 43.595 |
| 11:13 ET | 1084 | 43.595 |
| 11:15 ET | 727 | 43.6 |
| 11:18 ET | 100 | 43.6 |
| 11:20 ET | 200 | 43.49 |
| 11:24 ET | 300 | 43.395 |
| 11:26 ET | 500 | 43.26 |
| 11:29 ET | 100 | 43.23 |
| 11:31 ET | 200 | 43.145 |
| 11:33 ET | 200 | 43.155 |
| 11:36 ET | 300 | 43.145 |
| 11:38 ET | 100 | 43.11 |
| 11:40 ET | 100 | 43.06 |
| 11:42 ET | 5213 | 43.25 |
| 11:44 ET | 200 | 43.315 |
| 11:45 ET | 300 | 43.265 |
| 11:47 ET | 107 | 43.21 |
| 11:49 ET | 100 | 43.11 |
| 11:51 ET | 100 | 43.14 |
| 11:58 ET | 100 | 43.08 |
| 12:00 ET | 354 | 43.01 |
| 12:02 ET | 777 | 42.9835 |
| 12:03 ET | 600 | 43.0342 |
| 12:05 ET | 1949 | 42.915 |
| 12:07 ET | 100 | 42.79 |
| 12:09 ET | 510 | 42.92 |
| 12:12 ET | 200 | 42.91 |
| 12:18 ET | 100 | 42.9 |
| 12:20 ET | 1901 | 42.9 |
| 12:21 ET | 100 | 42.84 |
| 12:23 ET | 200 | 42.86 |
| 12:25 ET | 100 | 42.85 |
| 12:27 ET | 100 | 42.86 |
| 12:30 ET | 600 | 42.87 |
| 12:32 ET | 300 | 42.9 |
| 12:34 ET | 2143 | 42.92 |
| 12:38 ET | 265 | 42.9625 |
| 12:39 ET | 100 | 42.935 |
| 12:41 ET | 300 | 42.87 |
| 12:48 ET | 400 | 42.86 |
| 12:50 ET | 408 | 42.77 |
| 12:54 ET | 100 | 42.74 |
| 12:57 ET | 100 | 42.67 |
| 12:59 ET | 100 | 42.74 |
| 01:01 ET | 500 | 42.65 |
| 01:03 ET | 1107 | 42.59 |
| 01:06 ET | 100 | 42.6 |
| 01:08 ET | 3400 | 42.65 |
| 01:10 ET | 3873 | 42.715 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vericel Corp | 2.2B | 2,258.9x | --- |
Mirum Pharmaceuticals Inc | 2.0B | -16.3x | --- |
MannKind Corp | 1.7B | 175.2x | --- |
Zai Lab Ltd | 2.1B | -7.8x | --- |
Arrowhead Pharmaceuticals Inc | 2.7B | -4.2x | --- |
Maravai LifeSciences Holdings Inc | 2.1B | -8.3x | --- |
Company Information
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
Contact Information
- Headquarters
- 64 Sidney StCAMBRIDGE, MA, United States 02139
- Phone
- 734-930-5555
- Fax
- 734-665-0485
Executives
- Independent Chairman of the Board
- Robert Zerbe
- President, Chief Executive Officer, Director
- Dominick Colangelo
- Chief Financial Officer
- Joseph Mara
- Chief Operating Officer
- Michael Halpin
- Chief Human Resource Officer
- Karen Mahoney
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
|---|---|
Revenue (TTM) | $214.5M |
Shares Outstanding | 49.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.68 |
EPS | $0.02 |
Book Value | $4.72 |
P/E Ratio | 2,258.9x |
Price/Sales (TTM) | 10.5 |
Price/Cash Flow (TTM) | 378.7x |
Operating Margin | -1.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
